Mission

Catalyst Biosciences is developing the next generation of biopharmaceuticals by harnessing the catalytic power of engineered proteases.

Overview

Catalyst Biosciences is a drug discovery and development company that is creating novel catalytic biopharmaceutical products based on engineered human proteases.  Our mission is to establish protease therapeutics as a new therapeutic platform comparable in depth and scope to antibody pharmaceuticals.  The Company is developing proteases for the treatment of a broad range of diseases with a strong focus on hemostasis and inflammation. Proteases are well established as a class of drugs, with at least eight protease drugs on the market that generate over $5 billion in annual sales.  Catalyst is developing both improved and novel human proteases ("Alterase™ Therapeutics") to treat major diseases.

The Company’s product discovery platform is based on methods to rapidly create and characterize tailor-made protease drug candidates, called Alterase™ Therapeutics, that cleave disease-causing proteins or improve the biochemical and pharmacological properties of marketed protease drugs. Catalyst Biosciences has clearly demonstrated the advantages of protease therapeutics for important classes of disease targets in both in vivo animal studies and ex vivo human studies.

By engineering human proteases to alter their substrate specificity so that they can inactivate any given protein target or improve the pharmaceutical properties of marketed protease drugs, Catalyst Biosciences will vastly increase the use and application for therapeutic proteases, and create a new paradigm in target intervention.  The Company believes that the ability to target soluble or cell surface proteins involved in disease via an Alterase™ Therapeutic represents a significant opportunity for drug development.  The Company has assembled a team of world-class scientists and advisors, strong corporate partners, an enabling technology platform, and a robust pipeline, and is thus poised to become a fully integrated biopharmaceutical company with a diversified portfolio.